Sickle Cell Gene Therapy In Medicaid: CMMI Model As ‘Bandwidth Extender’ For Less Resourced States

Outcomes-based contract that federal government will negotiate with manufacturers on behalf of Medicaid programs might not be appealing to large states. Bluebird and Vertex can apply to the demonstration project this spring and negotiations would follow between May and November.

Working To Facilitate Access To High-Cost, Cutting Edge Therapy • Source: Shutterstock

The Center for Medicare and Medicaid Innovation’s new payment model for gene therapies for sickle cell disease in Medicaid got a cautious reception from bluebird bio and Vertex Pharmaceuticals Incorporated after it was announced on 30 January.

Uncertainty about whether the manufacturers of the two approved gene therapies for sickle cell disease could agree on a price...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet